Then, B16-F0 melanoma cells were inoculated subcutaneously and treated with anti-mouse CD8/CD4 antibodies to deplete CD8+ or CD4+ T cells, followed by anti-PD-1, butyrate, or combination treatment (Figure 4a). The gene discussed is CD8A; the disease is melanoma.